{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-018318","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-05-26T12:03:22+00:00","discovered_at":"2026-05-26T12:05:00.340648+00:00","generated_at":"2026-05-26T12:05:25.342304+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026","bullets":["In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).","Data from 18 patients across Acclaim-1 (osimertinib), Acclaim-2 (pembrolizumab), and Acclaim-3 (atezolizumab) trials.","High (3+) Trop-2 expression showed near-significant correlation with PFS (p=0.053); will be further investigated as biomarker.","In SCLC patients, Trop-2 levels were universally low; no significant correlation with PFS observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018318","json":"https://secwatch.observer/filing/0001437749-26-018318.json","markdown":"https://secwatch.observer/filing/0001437749-26-018318.md","text":"https://secwatch.observer/filing/0001437749-26-018318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/0001437749-26-018318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/gnpx20260515_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T12:05:25.342304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}